Laboratorio de Fibrosis y Cáncer, Facultad de Medicina y Cirugía, Universidad Autónoma Benito Juárez de Oaxaca, Ex Hacienda de Aguilera S/N, Sur, San Felipe del Agua, C.P. 68020, Oaxaca, México.
Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, C.P. 07360, Ciudad de México, México.
Biochem Genet. 2024 Dec;62(6):4280-4302. doi: 10.1007/s10528-024-10667-y. Epub 2024 Jan 31.
Recent research has shown that Doublecortin-like kinase 1 (DCLK1) is overexpressed in different types of cancer. It has recently been described as a cancer stem cells (CSCs) marker, is associated with carcinogenesis, and positively correlates with infiltration of multiple immune cell types in some cancers. However, studies focused on assessing DCLK1 expression in HCC are limited, and the role of DCLK1 in HCC tumor immunity remains to be determined. In this study, we used a modified model of the resistant hepatocyte (MRHM) to evaluate DCLK1 expression in HCC. Furthermore, DCLK1 expression in HCC was analyzed using TIMER 2.0, UALCAN, GEPIA, GEO, and HPA web-based tools. Correlations between DCLK1 expression and clinicopathological factors in patients were analyzed using the UALCAN web-based tool. Finally, correlations between DCLK1 and immune infiltrates were investigated using the TIMER 2.0 and TISIDB web-based tools. The results showed that DCLK1 is significantly overexpressed during progression of the HCC carcinogenic process in the MRHM. DCLK1 is overexpressed in HCC according to multiple publics web-based tools, and its overexpression is associated with cancer stage. Furthermore, DCLK1 expression was correlated with infiltration levels of multiple immune cells, immunomodulatory factors, immunoinhibitors, MHC molecules, chemokines, receptors, and immune cell-specific markers. These results suggest that DCLK1 is a potential prognostic biomarker that determines cancer progression and correlates with immune cell infiltration in HCC.
最近的研究表明,双皮质激酶 1(DCLK1)在多种癌症中过度表达。最近它被描述为癌症干细胞(CSCs)标志物,与肿瘤发生有关,并与一些癌症中多种免疫细胞类型的浸润呈正相关。然而,评估 HCC 中 DCLK1 表达的研究有限,DCLK1 在 HCC 肿瘤免疫中的作用仍有待确定。在这项研究中,我们使用改良的耐药肝细胞(MRHM)模型来评估 HCC 中 DCLK1 的表达。此外,使用 TIMER 2.0、UALCAN、GEPIA、GEO 和 HPA 等基于网络的工具分析 HCC 中 DCLK1 的表达。使用 UALCAN 基于网络的工具分析 DCLK1 表达与患者临床病理因素之间的相关性。最后,使用 TIMER 2.0 和 TISIDB 基于网络的工具研究 DCLK1 与免疫浸润之间的相关性。结果表明,在 MRHM 中 HCC 致癌过程的进展过程中,DCLK1 显著过表达。根据多个公共网络工具,DCLK1 在 HCC 中过表达,其过表达与癌症分期相关。此外,DCLK1 的表达与多种免疫细胞、免疫调节因子、免疫抑制剂、MHC 分子、趋化因子、受体和免疫细胞特异性标志物的浸润水平相关。这些结果表明,DCLK1 是一个潜在的预后生物标志物,决定着癌症的进展,并与 HCC 中的免疫细胞浸润相关。